Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 23,900 shares, an increase of 119.3% from the February 29th total of 10,900 shares. Based on an average trading volume of 23,500 shares, the days-to-cover ratio is presently 1.0 days. Currently, 2.8% of the company’s stock are short sold.

Virpax Pharmaceuticals Stock Down 2.8 %

Shares of NASDAQ:VRPX opened at $3.77 on Thursday. The firm’s 50 day moving average price is $3.60 and its 200 day moving average price is $5.06. The stock has a market cap of $4.41 million, a price-to-earnings ratio of -0.32 and a beta of 1.30. Virpax Pharmaceuticals has a fifty-two week low of $2.40 and a fifty-two week high of $11.77.

Hedge Funds Weigh In On Virpax Pharmaceuticals

A number of hedge funds have recently modified their holdings of VRPX. Citigroup Inc. purchased a new position in Virpax Pharmaceuticals in the 1st quarter valued at $27,000. Vanguard Group Inc. lifted its holdings in Virpax Pharmaceuticals by 4.5% in the first quarter. Vanguard Group Inc. now owns 341,977 shares of the company’s stock valued at $759,000 after acquiring an additional 14,672 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Virpax Pharmaceuticals in the first quarter valued at $348,000. 32.23% of the stock is currently owned by hedge funds and other institutional investors.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.